Braided antimicrobial suture

• US 20040068294A1
• Filed: 02/15/2003
• Published: 04/08/2004
• Est. Priority Date: 10/04/2002
• Status: Abandoned Application

• Current Assignee: Ethicon Incorporated (Johnson & Johnson)
• Original Assignee: Ethicon Incorporated (Johnson & Johnson)
• Inventors: Fischer, Jerome A., Scalzo, Howard
• Application Number:
  US10/367,565
• Publication Number:
  US 20040068294A1
• Time in Patent Office: Days
• US Class Current: 606/228
• CPC Class Codes: A61B 17/06114 Packages or dispensers for needles or sutures packages for sharps A61B50/3001; for dental floss A61C15/043; packages for needles in general B65D85/24
• CPC Class Codes: A61B 17/06166 Sutures suture materials A61L17/00; manufacture of artificial threads D01D; treatment of threads D06M
• CPC Class Codes: A61B 2017/00889 antimicrobial, disinfectant
• CPC Class Codes: A61L 17/005 containing a biologically active substance, e.g. a medicament or a biocide
• CPC Class Codes: A61L 2300/202 with halogen atoms, e.g. triclosan, povidone-iodine
• CPC Class Codes: A61L 2300/404 Biocides, antimicrobial agents, antiseptic agents
• CPC Class Codes: A61L 2300/606 Coatings

Abstract

A braided suture having antimicrobial properties comprising an elongate braided structure formed from a plurality of polymeric filaments, said filaments being formed from a polymeric material that is absorbable under physiological conditions; and a coating material disposed on said elongate braided structure, said coating comprising a film forming absorbable polymer, a substantially water-insoluble salt of a fatty acid and an effective amount of an antimicrobial agent selected from the group consisting of halogenated hydroxyl ethers, halogen-o-hydroxydiphenyl ethers, acyloxydiphenyl ethers and combinations thereof, said effective amount being sufficient to substantially inhibit microbial growth on or adjacent said suture when said suture is implanted in a patient'"'"'s body.

Claims

1. A braided suture having antimicrobial properties comprising:

an elongate braided structure formed from a plurality of polymeric filaments, said filaments being formed from a polymeric material that is absorbable under physiological conditions; and

a coating material disposed on said elongate braided structure, said coating comprising a film forming absorbable polymer, a substantially water-insoluble salt of a fatty acid and an effective amount of an antimicrobial agent selected from the group consisting of halogenated hydroxyl ethers, halogen-o-hydroxy-diphenyl ethers, acyloxydiphenyl ethers and combinations thereof, said effective amount being sufficient to substantially inhibit microbial growth on or adjacent said suture when said suture is implanted in a patient'"'"'s body.

2. The braided suture according to claim 1 having a first end and a second end, said braided suture having a needle fixedly attached to one end thereof.

3. The braided suture according to claim 1 wherein said antimicrobial agent is a halogenated 2-hydroxydiphenyl ether.

4. The braided suture according to claim 3 wherein said antimicrobial agent is 2,4,4′

-trichloro-2′

-hydroxydiphenyl ether.

5. The braided suture according to claim 1 wherein said effective amount of said antimicrobial agent is an amount sufficient to provide a minimum inhibitory concentration for S. aureus on a surface of said device.

6. The braided suture according to claim 5 wherein said concentration of said antimicrobial agent on said surface of said braided suture after said immersion of said suture in the physiological buffer for seven days is greater than the minimum inhibitory concentration for S. aureus or about 0.01 ppm (wt./wt. coating).

7. The braided suture of claim 1 wherein said effective amount of said antimicrobial agent is between about 30 ppm to about 5,000 ppm (wt./wt. suture) of 2,4,4′

-trichloro-2′

-hydroxydiphenyl ether.

8. The braided suture according to claim 1 wherein said polymeric material that is absorbable under physiological conditions is selected from a group of polymeric materials consisting of greater than about 70% polymerized glycolide, greater than about 70% polymerized lactide, polymerized 1,4-dioxan-2-one, greater than about 70% polypeptide, copolymers of glycolide and lactide, greater than about 70% cellulosics and cellulosic derivatives.

9. The braided suture according to claim 8 wherein said absorbable polymeric material is greater than 70% polymerized glycolide

10. The braided suture according to claim 9 wherein said polymeric material greater than 70% polymerized glycolide has a sufficient quantity of a dye added thereto to provide a color contrast to mammalian tissue.

12. The braided suture according to claim 8 having a first end and a second end, said braided suture having a needle fixedly attached to one end thereof.

14. The braided suture according to claim 5 wherein said effective amount of said antimicrobial agent is sufficient to provide a minimum inhibitory concentration for S. aureus on a surface of said device after an immersion of said suture in a physiological buffer for a minimum of seven days.

11. A braided suture having antimicrobial properties comprising:

an elongate braided structure formed from a plurality of filaments of a polymeric material comprising greater than about 70% polymerized glycolide;

a coating material disposed on said elongate braided structure, said coating comprising a film forming absorbable polymer, a substantially water-insoluble salt of a fatty acid and between about 30 ppm and 5000 ppm of 2,4,4′

-trichloro-2′

-hydroxydiphenyl ether for substantially inhibiting microbial growth on or adjacent said braided suture when said suture is implanted in a patient.

13. An improved braided suture having antimicrobial properties, said braided suture being an a elongate braided structure formed from a plurality of filaments comprising greater than about 70% polymerized glycolide and having a coating material disposed thereon, said coating material comprising a film forming absorbable polymer and a substantially water-insoluble salt of a fatty acid, wherein the improvement comprises said coating having incorporated therein between about 30 ppm and 5000 ppm (wt./wt. suture) of 2,4,4′

-trichloro-2′

-hydroxydiphenyl ether, thereby providing a concentration of more than about 0.01 ppm of said 2,4,4′

-trichloro-2′

-hydroxydiphenyl ether on a surface of said braided suture after immersion of said braided suture in a physiological buffer under physiological conditions for seven days, thereby substantially inhibiting opportunistic pathogenic microbial growth on or adjacent said braided suture when said suture is implanted in a patient